Market News

On 2 April 2026, the Sensex recovered after a sharp early fall and ended 185 points higher at 73,319.55. Nifty 50 added 34 points to finish at 22,713.10. IT stocks did most of the heavy lifting, with banks adding support.

Faced with disruptions in supply due to unrest in West Asia, the government has temporarily removed customs duties on 40 petrochemical products. This relief will remain in place until June 2026, though it is likely to cost the government around ₹1,800 crore in revenue.

More than two dozen companies have filed IPO draft papers in the last two days of FY26. This shows a strong pipeline with firms rushing to list in equity markets, and a growing investor appetite even during volatility.

Ola Electric shares rose up to 9% in intraday trade. In the process, it extended gains to over 20% in two sessions, after March registrations jumped and daily orders crossed 1,000 units.

Elon Musk’s SpaceX files for an IPO targeting a $1.75 trillion valuation and over a $50 billion raise, surpassing Saudi Aramco’s record listing.

Varun Beverages shares are in focus as the company announced the rescheduled record date for the final dividend payment on 8 April 2026, at ₹0.50 per share.

RBI nods to Emirates NBD’s ₹26,853 crore takeover of RBL Bank. With a ₹280 per share open offer expected, here’s what to watch next.

TVS Motor shares fell 3% despite 25% YoY sales growth to 5.19 lakh units in March. Global tensions and weak sentiment drove the dip. Read more for full insights.

Donald Trump hinted at a possible end to the Iran conflict, but mixed signals have kept markets uncertain. Experts warn that oil supply risks could continue to pressure global and Indian markets.

Rupee hits 95.125, oil jumps 44%, and $12B exits Indian equities. Analysts see rising odds of the rupee weakening to 100 per dollar. What’s next for the currency? Read the full analysis now.

Rediff has filed draft papers for an IPO through the confidential route. As per sources, it aims to raise ₹600–800 crore, as it shifts focus to AI, payments, and digital platforms after its 2024 acquisition.

Novo Nordisk has lowered the prices of its diabetes and weight-loss medications Ozempic and Wegovy by as much as 36% and 48% in India. The shift comes due to the expiry of patents and increasing competition with cheaper generics.